Zydus seeks DCGI approval for clinical trial of monoclonal antibodies cocktail
Zydus Cadila on Thursday announced that its biological therapy ZRC-3308, a cocktail of two SARS-CoV-2-neutralizing monoclonal antibodies (mAbs) can emerge as one of the main treatments for mild COVID-19.SARS-CoV-2 spike protein targeted,…